Onxeo S.A.
Stock Exchange Copenhagen Stock Exchange
EPS
DKK1.38
Market Cap
DKK328.23 M
Shares Outstanding
50.91 M
Public Float
-
Onxeo S.A.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
50.91 M
Public Float
-
Onxeo S.A.
Stock Exchange Euronext Paris
EPS
EUR0.18
Market Cap
EUR43.33 M
Shares Outstanding
54.82 M
Public Float
44.74 M

Profile

Address
49, blvd. du Général Martial Valin
Paris Ile-de-France 75015
France
Employees -
Website http://www.onxeo.com
Updated 07/08/2019
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA. The company was founded by Gilles Avenard and Dominique Costantini on March 5, 1997 and is headquartered in Paris, France.

Financials

View All
Created with Highcharts 5.0.14Onxeo S.A.Net Income. Fiscal year is January-December. All values EUR Thousands.15 32415 3247 6987 69819 40919 40922 67122 67159 07159 0719 3999 399201320142015201620172018010k20k30k40k50k60k70k
Created with Highcharts 5.0.14Onxeo S.A.Sales/Revenue. Fiscal year is January-December. All values EUR Thousands.1 4661 46622 08022 0803 4813 4814 4234 4239 5059 5056 1276 12720132014201520162017201805k10k15k20k25k

Judith Greciet
Chief Executive Officer & Director
Joseph S. Zakrzewski
Non-Executive Chairman